Intercept Pharma (ICPT) Impacts On Sales In PBC Should be Minimal - Needham
Tweet Send to a Friend
Needham & Company maintains Hold on Intercept Pharmaceuticals (NASDAQ: ICPT).Analyst Alan Carr assumes minimal impact on sales in PBC ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE